Modulating T cell responses for the treatment of psoriasis: A focus on efalizumab

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 361-370

  Cather, Jennifer Clay ^c   Cather, J Christian ^c   Menter, Alan ^a,b  

^a Texas Dermatology Associates PA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Anti CD11a; Efalizumab; Humanised monoclonal antibody; Leukocyte function associated antigen 1 (LFA 1); Psoriasis; T cell

Indexed keywords

CD11 ANTIGEN; CELL ADHESION MOLECULE; EFALIZUMAB; LIGAND; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT ANTIBODY;

ARTHRALGIA; ASTHENIA; BACKACHE; CHILL; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJURY; LOW DRUG DOSE; MYALGIA; NAUSEA; PAIN; PERIPHERAL EDEMA; PHARYNGITIS; PRURITUS; PSORIASIS; QUALITY OF LIFE; RELAPSE; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; T LYMPHOCYTE; TREATMENT OUTCOME; VERTIGO;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PSORIASIS; T-LYMPHOCYTES;

HERPES;

EID: 0348198461     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.361     Document Type: Review

References (42)

1. GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N. Engl. J. Med. (1995) 332:581-588.
2. GUENTHER LC, ORTONNE J-P: Pathophysiology of psoriasis: science behind therapy. J. Cutan. Med. Surg. (2002) 6(3 Suppl.):2-7.
3. CAMISA C: Psoriasis: a clinical update on diagnosis and new therapies. Cleve. Clin. J. Med. (2000) 67:105-119.
4. KRUEGER GG, FELDMAN SR, CAMISA C et al: considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J. Am. Acad. Dermatol. (2000) 43:281-285.
5. KRUEGER G, KOO J, LEBWOHL M, MENTER A, STERN RS, ROLSTAD T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. (2001)137:280-284.
6. FLEISCHER AB, FELDMAN SR, RAPP SR: Introduction. The magnitude of skin disease in the United States. Dermatol. Clin. (2000) 18:xv-xxi.
7. KOO J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Derm. Clin. (1996) 14:485-496.
8. LEBWOHL M, FELDMAN SR, WALTHER R, SHELK J, MORGAN, P, GUTKIN SW: Clinical management of psoriasis: principles and practice. Cutis. (2001) 67(1 Suppl.):1-15. Overview of traditional psoriasis therapies.
9. TRISTANI-FIROUZI P: Efficacy and safety of treatment modalities for psoriasis. Cutis. (1998) 61:11-21.
10. WEINSTEIN GD, WHITE GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J. Am. Acad. Dermatol. (1993) 28(3):454-459.
11. MUELLER W, HERMANN B: Cyclosporin A for psoriasis. N. Engl. J. Med. (1979) 301:555.
12. JEFFES EW 3RD, MCCULLOUGH JL, PITTELKOW MR et al: Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol. (1995) 104:183-188.
13. GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442-447.
14. MOREL P, REVILLARD JP, NICOLAS JF, WIJDENES J, RIZOVA H, THIVOLET J: Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. (1992) 5:465-477.
15. WEINSHENKER BG, BASS BH, EBERS GC, RICE GP: Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J. Am. Acad Dermatol. (1989) 20:1132-1133.
16. RAYCHAUDHURI SP, DUTT S, RAYCHAUDHURI SK, SANYAL M, FARBER EM: Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br. J. Dermatol. (2001) 144(5):931-939.
17. KIRBY B, GRIFFITHS CEM: Novel immune-based therapies for psoriasis. Br. J. Dermatol (2002) 146:546-551. Review of biological agents for psoriasis and their mechanisms of action.
18. SINGRI P, WEST DP, GORDON KB: Biologic therapy for psoriasis: the new therapeutic frontier. Arch. Dermatol. (2002) 138:686-688. Review article on the biological agents being developed for psoriasis and their mechanisms of action.
19. DUSTIN ML, SPRINGER TA: Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Ann. Rev. Immunol. (1991) 9:26-66.
20. ROTHLEIN R, DUSTIN ML, MARLIN SD, SPRINGER TA: A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. (1986) 137:1270-1274.
21. DUSTIN ML, STAUNTON DE, SPRINGER TA: Supergene families meet in the immune system. Immunol. Today (1988) 9:213-215. Review of cell adhesion molecules and their function in T cell adhesion and activation.
22. FISCHER A, DURANDY A, STERKERS G, GRISCELLI C: Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. J. Immunol. (1986) 136:198-203.
23. SPRINGER TA, DUSTIN ML, KISHIMOTO TK, MARLIN SD: The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system [review]. Ann. Rev. Immunol. (1987) 5:223-252.
24. WERTHER WA, GONZALEZ TN, O'CONNOR SJ et al.: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. (1996) 157:4986-4995.
25. NICKOLOFF BJ, BASHAM TY, MERIGAN TC, MORHENN VB: Keratinocyte class II histocompatibility antigen expression. Br. J. Dermatol. (1985) 112:373-374.
26. NICKOLOFF BJ: The role of gamma interferon in epidermal trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch. Dermatol. (1988) 124:1835-1843.
27. KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. (2002) 46:1-23.
28. GRAKOUI A, BROMLEY SK, SUMEN C et al.: The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221-227. Review of the immunologic synapse and its role in T cell activation.
29. HILDRETH JE, AUGUST JT: The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): functional effects of subunit-specific monoclonal antibodies. J. Immunol. (1985) 134:3272-3280.
30. DOUGHERTY GJ, HOGG N: The role of monocyte lymphocyte function-associated antigen 1 (LFA-1) in accessory cell function. Eur. J. Immunol. (1987) 17:943-947.
31. KRUEGER J, GOTTLIEB A, MILLER B et al.: Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J. Invest. Dermatol. (2000) 115:333.
32. LOWE J, STEFANICH E, RANGELL L, PIPPIG S: Efalizumab (and-CD11a) inhibits transendothelial migration of T cells. Poster presented at Society of Investigative Dermatology, Los Angeles, California, May 15-18 (2002).
33. BAUER RJ, DEDRICK RL, WHITE ML, MURRAY MJ, GAROVOY MR: Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1 124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. (1999) 27:397-420.
34. DUMMER W, JOSHI A, BEYER J et al.: Pharmacodynamic effects of subcutaneous (SC) administration of efalizumab (anti-CD11a). 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22-27 (2002).
35. GOTTLIEB A, KRUEGER JG, BRIGHT R et al.: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad Dermatol. (2000) 42:428-435.
36. PAPP K, BISSONNETTE R, KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. (2001) 45:665-674.
37. GOTTLIEB AB, KRUEGER JG, WITTKOWSKI K, DEDRICK R, WALICKE PA, GAROVOY M: Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. J. Am. Acad. Dermatol. (2002) 138:591-600.
38. GOTTLIEB AB, MILLER B, CHAUDHARI U et al.: Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1 124) in patients with psoriasis. Poster presented at Society of Investigative Dermatology, Chicago, Illinois, May 10 (1999).
39. KRUEGER J, GOTTLIEB AB, MILLER B, DEDRICK R, GAROVOY M, WALICKE P: Anti-CD11a (hu1 124) treatment for psoriasis concurrently increases circulating T cells and decreases plaque T cells, consistent with inhibition of cutaneous T-cell trafficking. Poster presented at Society of Investigative Dermatology, Chicago, Illinois, May 10-14 (2000).
40. LEONARDI CL, GOTTLIEB AB, MILLER B, TASHJIAN D, PARISER D, SHAPIRO W et al.: Efalizumab (anti-CD11a): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at American Association of Dermatology, Washington DC, March 2-7 (2001).
41. LEONARDI C et al.: Efalizumab (Raptiva™) - an overview. J. Am. Acad. Dermatol. (in press). Phase III data (safety and efficacy) for psoriasis patients treated with efalizumab.
42. BOYD AS, MENTER A: Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J. Am. Acad. Dermatol. (1989) 21:985-991.